
Coherus Oncology, Inc. (NASDAQ:CHRS – Free Report) – Investment analysts at HC Wainwright dropped their FY2026 earnings estimates for Coherus Oncology in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings of ($0.89) per share for the year, down from their prior forecast of ($0.84). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Coherus Oncology’s current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for Coherus Oncology’s Q4 2026 earnings at ($0.22) EPS, Q1 2027 earnings at ($0.18) EPS, Q2 2027 earnings at ($0.18) EPS, Q3 2027 earnings at ($0.18) EPS, Q4 2027 earnings at ($0.14) EPS, FY2027 earnings at ($0.68) EPS, FY2028 earnings at ($0.54) EPS and FY2029 earnings at ($0.26) EPS.
Other research analysts have also issued reports about the company. Weiss Ratings lowered Coherus Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, November 10th. Wall Street Zen raised shares of Coherus Oncology from a “sell” rating to a “hold” rating in a research report on Sunday. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.
Coherus Oncology Price Performance
Shares of NASDAQ CHRS opened at $0.37 on Friday. The firm has a market cap of $57.13 million, a P/E ratio of -0.38 and a beta of 1.03. The business’s 50 day moving average is $0.97 and its 200-day moving average is $1.43. The company has a current ratio of 1.51, a quick ratio of 1.45 and a debt-to-equity ratio of 2.08. Coherus Oncology has a 1-year low of $0.36 and a 1-year high of $2.62.
Coherus Oncology (NASDAQ:CHRS – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The biotechnology company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.03). Coherus Oncology had a negative net margin of 253.43% and a negative return on equity of 274.46%. The company had revenue of $14.27 million during the quarter, compared to analyst estimates of $15.90 million.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. bought a new position in shares of Coherus Oncology in the second quarter valued at approximately $16,805,000. Goldman Sachs Group Inc. lifted its holdings in shares of Coherus Oncology by 231.4% during the third quarter. Goldman Sachs Group Inc. now owns 1,995,469 shares of the biotechnology company’s stock valued at $2,415,000 after purchasing an additional 1,393,394 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of Coherus Oncology in the second quarter worth approximately $531,000. Sei Investments Co. increased its holdings in Coherus Oncology by 492.2% in the 1st quarter. Sei Investments Co. now owns 453,763 shares of the biotechnology company’s stock worth $767,000 after acquiring an additional 377,134 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Coherus Oncology in the second quarter worth about $448,000. 72.82% of the stock is owned by institutional investors and hedge funds.
Coherus Oncology News Roundup
Here’s some of the latest news about CHRS:
- Negative Sentiment: HC Wainwright trimmed estimates for FY2026–FY2029, including FY2026 EPS from ($0.84) to ($0.89), FY2027 from ($0.63) to ($0.68), FY2028 from ($0.48) to ($0.54), and FY2029 from ($0.19) to ($0.26). It also lowered estimates for Q4 2026 and each quarter of 2027. These revisions point to greater expected losses in the near term and beyond. MarketBeat coverage
- Neutral Sentiment: Despite lowering its forecasts, HC Wainwright kept its Buy rating on CHRS. MarketBeat coverage
Coherus Oncology Company Profile
Coherus Oncology, formerly Coherus BioSciences, is a biopharmaceutical company focused on developing and commercializing cancer treatments. Its portfolio includes LOQTORZI (toripalimab-tpzi), an immune checkpoint inhibitor that targets PD-1 and is approved in the United States for certain patients with nasopharyngeal cancer. The company is also advancing a pipeline of investigational immuno-oncology medicines. Coherus historically built its business around biosimilar medicines before shifting its focus to oncology.
Featured Stories
- Five stocks we like better than Coherus Oncology
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Coherus Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
